Profile data is unavailable for this security.
About the company
Diurnal Group plc is a specialty pharmaceutical company. It is focused on developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. It focuses on addressing unmet clinical and patient needs in hormone replacement by developing and marketing products for the rare and orphan diseases Congenital Adrenal Hyperplasia (CAH) and Adrenal Insufficiency (AI). The Company’s products include Alkindi and Efmody. Its product Alkindi (hydrocortisone granules in capsules for opening) is a specifically designed for young children suffering from paediatric AI, and the related condition CAH. Its product Efmody (modified-release hydrocortisone) provides a drug release profile that is designed to improve disease treatment for adults with CAH, as measured by androgen (male sex hormone) control. Its pipeline includes DNL-0200, DNL-0300, DNL-0400 and DNL-0500.
- Revenue in GBP (TTM)5.28m
- Net income in GBP-13.34m
- Incorporated2015
- Employees36.00
- LocationDiurnal Group PLCHeath ParkCARDIFF CF14 4UJUnited KingdomGBR
- Phone+44 292 068 2069
- Websitehttp://www.diurnal.co.uk/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Evgen Pharma PLC | 0.00 | -2.73m | 9.48m | 11.00 | -- | 1.03 | -- | -- | -0.0099 | -0.0099 | 0.00 | 0.0336 | 0.00 | -- | -- | 0.00 | -24.76 | -42.32 | -25.95 | -46.45 | -- | -- | -- | -6,869.07 | -- | -- | 0.00 | -- | -100.00 | -- | -2.09 | -- | -47.61 | -- |
| Proteome Sciences plc | 5.13m | 72.00k | 10.63m | 27.00 | 211.76 | -- | 37.29 | 2.07 | 0.0002 | 0.0002 | 0.017 | -0.0094 | 0.536 | 2.21 | 4.41 | 189,963.00 | 0.7524 | -7.87 | -- | -- | 57.71 | 59.94 | 1.40 | -15.71 | 0.2961 | 1.40 | 1.31 | -- | 7.91 | 13.33 | -75.59 | -- | 43.95 | -- |
| Kanabo Group PLC | 73.00k | -4.55m | 11.00m | 0.00 | -- | 1.86 | -- | 150.63 | -0.0144 | -0.0144 | 0.0002 | 0.014 | 0.0228 | -- | 0.3296 | -- | -142.42 | -- | -153.70 | -- | 9.59 | -- | -6,234.25 | -- | 11.43 | -- | 0.00 | -- | -- | -- | -3,374.05 | -- | -- | -- |
| Fusion Antibodies PLC | 4.70m | -3.01m | 11.97m | 54.00 | -- | 2.81 | -- | 2.55 | -0.1159 | -0.1159 | 0.1813 | 0.1638 | 0.6874 | 5.02 | 3.26 | 87,055.55 | -44.04 | -21.34 | -50.93 | -24.71 | 50.03 | 47.45 | -64.07 | -36.64 | 3.57 | -166.88 | 0.0346 | -- | 6.93 | 22.97 | -315.93 | -- | 59.14 | -- |
| Hemogenyx Pharmaceuticals PLC | 0.00 | -5.10m | 12.74m | 10.00 | -- | 1.55 | -- | -- | -0.0081 | -0.0081 | 0.00 | 0.0084 | 0.00 | -- | -- | 0.00 | -91.34 | -96.46 | -112.36 | -120.13 | -- | -- | -- | -- | -- | -1.05 | 0.0012 | -- | -- | -- | -144.89 | -- | 34.08 | -- |
| Abingdon Health PLC | 5.64m | -12.85m | 13.39m | 151.00 | -- | 0.6133 | -- | 2.38 | -0.0949 | -0.0949 | 0.03 | 0.1794 | 0.1581 | 0.8421 | 0.6699 | 37,317.88 | -36.04 | -- | -49.56 | -- | -1.38 | -- | -228.02 | -- | 1.48 | -167.05 | 0.0572 | -- | 121.93 | -- | -106.69 | -- | -- | -- |
| Oxford Biodynamics PLC | 176.00k | -6.63m | 13.55m | 39.00 | -- | 2.06 | -- | 76.97 | -0.0695 | -0.0695 | 0.0018 | 0.0655 | 0.0133 | -- | 0.1832 | 4,512.82 | -50.16 | -24.63 | -57.11 | -26.67 | -- | -- | -3,768.18 | -480.92 | 2.80 | -- | 0.4983 | -- | -25.22 | -20.75 | -53.64 | -- | 71.53 | -- |
| Shield Therapeutics PLC | 1.95m | -13.04m | 16.21m | 16.00 | -- | 0.3174 | -- | 8.32 | -0.0817 | -0.0817 | 0.0122 | 0.2363 | 0.043 | 0.5348 | 1.54 | 121,812.50 | -28.76 | -24.56 | -30.15 | -27.03 | 61.31 | 89.95 | -668.91 | -199.87 | 17.86 | -451.48 | 0.00 | -- | 1,344.65 | -- | 70.11 | -- | -29.49 | -- |
| IXICO PLC | 8.20m | 949.00k | 17.09m | 93.00 | 18.97 | 1.48 | 10.83 | 2.08 | 0.0187 | 0.0187 | 0.162 | 0.2398 | 0.6088 | -- | 2.99 | 88,161.29 | 7.04 | 1.59 | 8.19 | 2.13 | 61.59 | 63.73 | 11.56 | 2.11 | -- | 23.00 | 0.0451 | 0.00 | -3.59 | 22.97 | 65.44 | -- | 145.81 | -- |
| MiLOC Group Limited | 1.05m | 2.07m | 17.10m | 6.00 | 8.37 | -- | -- | 16.23 | 0.0238 | 0.0238 | 0.0123 | -0.0476 | 0.638 | 1.75 | 4.21 | -- | 98.95 | -111.75 | -- | -- | 23.02 | 39.32 | 155.09 | -146.30 | 0.083 | 42.56 | -- | -- | 32.56 | 19.76 | 124.34 | -- | 24.85 | -- |
| OptiBiotix Health PLC | 1.85m | 20.68m | 18.05m | 8.00 | 0.9764 | 0.6903 | 0.8618 | 9.74 | 0.21 | 0.21 | 0.0185 | 0.297 | 0.1045 | 8.01 | 2.21 | 231,808.80 | 116.55 | 5.69 | 120.40 | 6.03 | 57.00 | 61.06 | 1,114.96 | 64.92 | 3.72 | -- | 0.0298 | -- | 104.50 | 122.08 | 345.09 | -- | 181.84 | -- |
| Genincode PLC | 1.15m | -4.14m | 18.21m | 20.00 | -- | 1.33 | -- | 15.78 | -0.0432 | -0.0432 | 0.012 | 0.1432 | 0.1309 | 34.89 | 3.56 | 57,700.00 | -46.98 | -- | -51.02 | -- | 51.39 | -- | -358.93 | -- | 18.00 | -- | 0.00 | -- | 20.11 | -- | -255.23 | -- | -- | -- |
| Diurnal Group PLC | 5.28m | -13.34m | 18.24m | 36.00 | -- | 0.6078 | -- | 3.45 | -0.0839 | -0.0839 | 0.0335 | 0.1769 | 0.1734 | 0.5198 | 7.80 | 146,722.20 | -43.79 | -43.08 | -50.20 | -50.33 | 83.13 | -- | -252.54 | -427.57 | 7.13 | -22.99 | 0.00 | -- | -30.76 | -- | -146.78 | -- | -- | -- |
| Provexis plc | 479.46k | -283.34k | 18.30m | 2.00 | -- | 11.74 | -- | 38.16 | -0.0001 | -0.0001 | 0.0002 | 0.0007 | 0.6028 | 0.5587 | 4.05 | 239,730.00 | -37.93 | -96.20 | -26.38 | -55.13 | 89.01 | 89.81 | -62.92 | -133.98 | 6.32 | -- | 0.00 | -- | 45.23 | 40.70 | 16.05 | -- | -- | -- |
Data as of Jul 01 2022. Currency figures normalised to Diurnal Group PLC's reporting currency: UK Pound GBX
36.97%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Polar Capital LLPas of 04 Nov 2021 | 18.67m | 11.00% |
| Chelverton Asset Management Ltd.as of 13 Sep 2021 | 9.75m | 5.75% |
| J.O. Hambro Capital Management Ltd.as of 06 Jan 2022 | 8.44m | 4.97% |
| BGF Investment Management Ltd.as of 13 Sep 2021 | 7.54m | 4.44% |
| Hargreaves Lansdown Stockbrokers Ltd.as of 02 Apr 2022 | 4.21m | 2.48% |
| SVM Asset Management Ltd.as of 31 Dec 2021 | 3.30m | 1.94% |
| Oceanwood Capital Management LLPas of 20 Sep 2019 | 3.15m | 1.86% |
| Walker Crips Investment Management Ltd.as of 02 Apr 2022 | 2.68m | 1.58% |
| IG Markets Ltd.as of 02 Apr 2022 | 2.57m | 1.52% |
| Hargreaves Lansdown Asset Management Ltd.as of 02 Apr 2022 | 2.44m | 1.44% |
More ▼
Data from 31 Dec 2021 - 17 Jun 2022Source: FactSet Research Systems Inc.
